Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer

Journal of Thoracic Oncology

Volumn 10, Issue 3, 2015, Pages 426-430

  Ishii, Hidenobu ^a   Azuma, Koichi ^a   Kawahara, Akihiko ^b   Yamada, Kazuhiko ^a   Imamura, Yohei ^a   Tokito, Takaaki ^a   Kinoshita, Takashi ^a   Kage, Masayoshi ^b   Hoshino, Tomoaki ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY HOSPITAL   (Japan)

Author keywords

Immunohistochemistry; PD L1; Prognostic factor; Small cell lung cancer

Indexed keywords

CISPLATIN; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SMALL CELL LUNG CANCER; VERY ELDERLY; ENZYME IMMUNOASSAY; FOLLOW UP; LUNG TUMOR; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; BIOMARKERS, TUMOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 84926421308     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000414     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A, Cancer statistics, 2012. CA Cancer J Clin 2012 62 10 29
2. Ettinger DS, Overview and state of the art in the management of lung cancer. Oncology 2004 18 3 9
3. Pardoll DM, The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012 12 252 264
4. Dong H, Strome SE, Salomao DR, Tumor-Associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002 8 793 800
5. Parsa AT, Waldron JS, Panner A, Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007 13 84 88
6. Topalian SL, Hodi FS, Brahmer JR, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 366 2443 2454
7. Brahmer JR, Tykodi SS, Chow LQ, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012 366 2455 2465
8. Brahmer JR, Drake CG, Wollner I, Phase I study of single-Agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010 28 3167 3175
9. Taube JM, Anders RA, Young GD, Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012 4 127 137
10. Yang CY, Lin MW, Chang YL, Wu CT, Yang PC, Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014 50 1361 1369
11. Chen YB, Mu CY, Huang JA, Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: A 5-year-follow-up study. Tumori 2012 98 751 755
12. Velcheti V, Schalper KA, Carvajal DE, Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014 94 107 116
13. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG, High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011 28 682 688
14. Droeser RA, Hirt C, Viehl CT, Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013 49 2233 2242
15. Schalper KA, Velcheti V, Carvajal D, In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 2014 20 2773 2782
16. Hino R, Kabashima K, Kato Y, Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010 116 1757 1766
17. Lipson EJ, Vincent JG, Loyo M, PD-L1 expression in the Merkel cell carcinoma microenvironment: Association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013 1 54 63
18. Ohigashi Y, Sho M, Yamada Y, Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005 11 2947 2953
19. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N, Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006 108 19 24
20. Gao Q, Wang XY, Qiu SJ, Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009 15 971 979
21. Nomi T, Sho M, Akahori T, Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007 13 2151 2157
22. Thompson RH, Dong H, Kwon ED, Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 2007 13 709s 715s
23. Thompson RH, Gillett MD, Cheville JC, Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 2005 104 2084 2091
24. Thompson RH, Gillett MD, Cheville JC, Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 2004 101 17174 17179
25. Thompson RH, Kwon ED, Significance of B7-H1 overexpression in kidney cancer. Clin Genitourin Cancer 2006 5 206 211
26. Hamanishi J, Mandai M, Iwasaki M, Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007 104 3360 3365
27. Parsa AT, Waldron JS, Panner A, Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007 13 84 88
28. Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS, The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2013 19 598 609
29. Crane CA, Panner A, Murray JC, PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene 2009 28 306 312
30. Akbay EA, Koyama S, Carretero J, Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013 3 1355 1363